missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Human EphA2 Antibody, R&D Systems™

Mouse Monoclonal Antibody has been used in 4 publications
Brand: R&D Systems MAB3035
This item is not returnable.
View return policy
Description
EphA2 Monoclonal specifically detects EphA2 in Human samples. It is validated for Flow Cytometry, Immunocytochemistry, CyTOF-ready, Knockout Validated.
Specifications
| EphA2 | |
| Monoclonal | |
| LYOPH | |
| Flow Cytometry 0.25 ug/10^6 cells, Immunocytochemistry 8-25 ug/mL, CyTOF-ready, Knockout Validated 5 ug/mL | |
| P29317 | |
| EPHA2 | |
| Mouse myeloma cell line NS0-derived recombinant human EphA2 Gln25-Asn534 Accession # P29317 | |
| 100 μg | |
| Primary | |
| Detects human EphA2 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant mouse EphA4, A5, A6, A7, A8, or recombinant rat EphB1 is observed. | |
| Human | |
| Purified |
| Flow Cytometry, Immunocytochemistry, CyTOF, KnockDown | |
| 371805 | |
| Unconjugated | |
| Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
| ARCC2, EC 2.7.10, EC 2.7.10.1, Eck, ECKepithelial cell receptor protein tyrosine kinase, EPH receptor A2, EphA2, ephrin type-A receptor 2, Epithelial cell kinase, Myk2, Sek2, soluble EPHA2 variant 1, Tyrosine-protein kinase receptor ECK | |
| Mouse | |
| Protein A or G purified from hybridoma culture supernatant | |
| RUO | |
| 1969 | |
| Reconstitute at 0.5 mg/mL in sterile PBS. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
| IgG2a |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction